googlefd16b42746daa692.html

CAR T cells and infection risk

blood 2017 car t.png

Next gen immunotherapies, such as CAR T cells, have well and truly revolutionised cancer treatment and cure. However, in modifying the immune system (in this case- lymphodepletion with CD19- targeted CAR T cell therapy) there is a potential for altering risk of infection. In this months edition of Blood, Hill et al, retrospectively reviewed the incidence of infections following CD19 CAR T cell therapy in n=133 patients. Key findings include: a risk of infection similar to conventional chemotherapy and that modification of the treatment regimen, specifically- to reduce Cytokine Release Syndrome severity, decreased the frequency of infections. 

With the explosion of next gen immunotherapies in cancer treatment we are excited to see more studies of this nature.

googlefd16b42746daa692.html